Compare · MDLN vs QNRX
MDLN vs QNRX
Side-by-side comparison of Medline Inc. (MDLN) and Quoin Pharmaceuticals Ltd. (QNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and QNRX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 2483.3x QNRX ($19.4M).
- Over the past year, MDLN is down 11.8% and QNRX is down 73.4% - MDLN leads by 61.6 points.
- QNRX has been more active in the news (11 items in the past 4 weeks vs 7 for MDLN).
- MDLN has more recent analyst coverage (25 ratings vs 2 for QNRX).
PerformanceMDLN-11.77%QNRX-69.98%
2025-12-17+0.00%2026-10-16
- Company
- Medline Inc.
- Quoin Pharmaceuticals Ltd.
- Price
- $35.95-1.74%
- $4.03+0.25%
- Market cap
- $48.08B
- $19.4M
- 1M return
- +11.97%
- -41.34%
- 1Y return
- -11.77%
- -73.36%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2016
- News (4w)
- 7
- 11
- Recent ratings
- 25
- 2
QNRX
Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest QNRX
- SEC Form 8-K filed by Quoin Pharmaceuticals Ltd.
- Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
- BTIG Research initiated coverage on Quoin Pharmaceuticals with a new price target
- Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
- SEC Form DEF 14A filed by Quoin Pharmaceuticals Ltd.
- SEC Form EFFECT filed by Quoin Pharmaceuticals Ltd.
- SEC Form 424B3 filed by Quoin Pharmaceuticals Ltd.
- Lake Street initiated coverage on Quoin Pharmaceuticals with a new price target
- SEC Form PRE 14A filed by Quoin Pharmaceuticals Ltd.
- Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits